Liver Diseases Research
The Division of Liver Diseases at Mount Sinai conducts vital new research that promises to improve patient care. As faculty at the Icahn School of Medicine at Mount Sinai, our physicians are examining new antiviral drug combinations to treat and manage chronic hepatitis B and C, conditions that affect more than 500 million people worldwide, according to the Centers for Disease Control and Prevention.
As part of our team, the Hepatitis Outreach Network (HONE) provides screenings at no cost at a variety of health fairs and ethnic communities throughout New York City as part of a larger study in viral hepatitis prevention.
Our vast experience in treating patients with all types of liver diseases and our partnership with other specialties at Mount Sinai helps to guide our research. As a multidisciplinary group, we strive to advance knowledge in the following areas:
- Viral hepatitis diagnosis and treatment
- The basis for fibrosis (scarring) and cirrhosis of the liver and their treatments
- Liver disease associated with obesity and diabetes
- Autoimmune diseases of the liver and bile ducts
- Nonalcoholic fatty liver disease
- Alcohol liver disease
- Complications of cirrhosis
- Early detection and treatment of liver cancer
- Hepatocellular carcinomas
- Liver transplantation
This innovative research paves the way for our patients to learn and participate in clinical trials of new therapies for liver disease. Some of these clinical trials include interferon-free regimens for hepatitis C, as well as studies that involve preventing liver fibrosis (scarring) and new techniques in diagnosing fatty liver disease and primary biliary cirrhosis.
There has never been a time in medical progress when clinical trials in liver disease have been more important than they are right now. Mount Sinai Liver doctors are pioneering the use of many new drugs for hepatitis C, hepatitis B, and liver cancer.
There are over 40 new drugs for hepatitis C undergoing testing now in the United States and we are participating in clinical trials at Mount Sinai in many of them. We firmly believe that to provide the best possible clinical care, we must make clinical trials available to our patients. This gives patients the option to enroll in cutting-edge research of new drugs before they are on the market. Mount Sinai offers patients clinical trials with interferon-free medications, which is a new oral treatment without the side effects often associated with interferon drugs.
Clinical trials for preventing liver fibrosis (scarring), measuring fibrosis without liver biopsy with a machine called a Fibroscan, for fatty liver and for primary biliary cirrhosis are all ongoing in various stages at the Division for Liver Diseases.
Mount Sinai laboratory researchers work hand-in-hand with our team of clinical researchers, studying liver disease from lab bench to bedside. Teams of physician-scientists meet daily to develop short and long-term research agendas to keep Mount Sinai on the cutting-edge of medical science. All these factors translate into doing the best research so we can provide superb clinical care to our patients and offer them the best options for treatment for all liver diseases.
Our research is supported by a number of sources, including the National Institutes of Health, and the findings are shared with physicians worldwide through publication in peer-reviewed medical journals. The result is that we are able to deliver cutting-edge treatments to our patients.
Search our clinical trials.